ES2190819T3 - Procedimiento de preparacion de formulaciones galenicas noveles que contienen fenobrinato, formulaciones galenicas asi obtenidas y sus aplicaciones. - Google Patents

Procedimiento de preparacion de formulaciones galenicas noveles que contienen fenobrinato, formulaciones galenicas asi obtenidas y sus aplicaciones.

Info

Publication number
ES2190819T3
ES2190819T3 ES99941732T ES99941732T ES2190819T3 ES 2190819 T3 ES2190819 T3 ES 2190819T3 ES 99941732 T ES99941732 T ES 99941732T ES 99941732 T ES99941732 T ES 99941732T ES 2190819 T3 ES2190819 T3 ES 2190819T3
Authority
ES
Spain
Prior art keywords
galenic formulations
phenobrinate
procedure
applications
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99941732T
Other languages
English (en)
Inventor
Claude Laruelle
Rene Gimet
Dominique Toselli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLL Pharma SA
Original Assignee
CLL Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9530543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2190819(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CLL Pharma SA filed Critical CLL Pharma SA
Application granted granted Critical
Publication of ES2190819T3 publication Critical patent/ES2190819T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procedimiento de preparación de una formulación galénica que comprende fenofibrato como principio activo, caracterizado porque comprende las siguientes etapas: (a) la micronización del fenofibrato; (b) la granulación del fenofibrato así micronizado en presencia de un medio líquido que comprende un agente tensioactivo, agua y un alcohol miscible con agua; y (c) el secado del granulado así obtenido.
ES99941732T 1998-09-17 1999-09-10 Procedimiento de preparacion de formulaciones galenicas noveles que contienen fenobrinato, formulaciones galenicas asi obtenidas y sus aplicaciones. Expired - Lifetime ES2190819T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9811611A FR2783421B1 (fr) 1998-09-17 1998-09-17 Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications

Publications (1)

Publication Number Publication Date
ES2190819T3 true ES2190819T3 (es) 2003-08-16

Family

ID=9530543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99941732T Expired - Lifetime ES2190819T3 (es) 1998-09-17 1999-09-10 Procedimiento de preparacion de formulaciones galenicas noveles que contienen fenobrinato, formulaciones galenicas asi obtenidas y sus aplicaciones.

Country Status (16)

Country Link
EP (1) EP1112064B1 (es)
JP (1) JP2002526438A (es)
KR (1) KR100712032B1 (es)
AT (1) ATE230979T1 (es)
AU (1) AU5523599A (es)
BR (1) BR9913782A (es)
CA (1) CA2342742A1 (es)
CZ (1) CZ298634B6 (es)
DE (1) DE69904954D1 (es)
ES (1) ES2190819T3 (es)
FR (1) FR2783421B1 (es)
MX (1) MXPA01002801A (es)
PL (1) PL194847B1 (es)
SK (1) SK284950B6 (es)
WO (1) WO2000016749A1 (es)
ZA (1) ZA200101894B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
FR2819720B1 (fr) 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1553928A1 (en) * 2002-09-24 2005-07-20 Ranbaxy Laboratories, Ltd. Oral pharmaceutical compositions of fenofibrate having high bioavailability
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP2842547A1 (en) 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Improved fenofibrate compositions
EP2878311A1 (en) 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Solubility Enhancement for Hydrophobic Drugs
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
CN104352466A (zh) * 2014-11-17 2015-02-18 辰欣药业股份有限公司 一种非诺贝特组合物及其制剂
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
DE19608750A1 (de) * 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Verfahren zur Herstellung von Fenofibrat-Präparaten
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation

Also Published As

Publication number Publication date
CZ2001979A3 (cs) 2001-08-15
EP1112064B1 (fr) 2003-01-15
MXPA01002801A (es) 2002-04-08
CA2342742A1 (fr) 2000-03-30
FR2783421B1 (fr) 2000-11-24
CZ298634B6 (cs) 2007-11-28
FR2783421A1 (fr) 2000-03-24
BR9913782A (pt) 2001-06-05
PL346714A1 (en) 2002-02-25
EP1112064A1 (fr) 2001-07-04
SK3552001A3 (en) 2001-09-11
KR100712032B1 (ko) 2007-04-27
WO2000016749A1 (fr) 2000-03-30
PL194847B1 (pl) 2007-07-31
ZA200101894B (en) 2003-01-07
AU5523599A (en) 2000-04-10
JP2002526438A (ja) 2002-08-20
KR20010075182A (ko) 2001-08-09
DE69904954D1 (de) 2003-02-20
SK284950B6 (sk) 2006-03-02
ATE230979T1 (de) 2003-02-15

Similar Documents

Publication Publication Date Title
ES2190819T3 (es) Procedimiento de preparacion de formulaciones galenicas noveles que contienen fenobrinato, formulaciones galenicas asi obtenidas y sus aplicaciones.
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
AR010579A1 (es) Composicion de limpieza y desinfeccion acuosa lista para usar y proceso para desinfeccion de superficies duras.
MA26922A1 (fr) Procede de preparation d'une composition
ATE415943T1 (de) Pharmazeutische zubereitungen enthaltend einen amphoteren emulgator, polyproxylierten cetylalkohol und einen polaren wirkstoff
DE69414840D1 (de) Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff
ES2107851T3 (es) Formulacion acabada, estable, polifasica, acuosa, para productos activos protectores de las plantas y procedimiento para su obtencion.
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
BRPI0511704A (pt) formulações aquosas com pouca espuma como defensivo para plantas
EE200300235A (et) Ravimpreparaat, milles aktiivne ingredient on ühtlaselt dispergeeritud abiainete alussegus, ning seda sisaldav doseerimisvorm
ES2157731B1 (es) Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
MXPA05010196A (es) Nuevas formulaciones y su uso.
HRP20020844B1 (hr) Tekuće formulacije
DE69418468D1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
IL208697A0 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
MXPA03006999A (es) Composicion limpiadora espumante suave.
ES2139071T3 (es) Agente insecticida y acaricida derivado del triazol y proceso para la produccion del mismo.
CU22836A3 (es) Sistema de gel de nimesulida para uso tópico
DE60119082D1 (de) Anästhetikum enthaltende formulierungen
AR032545A1 (es) Composiciones parasiticidas y metodos de uso
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
DK1441769T3 (da) Farmaceutiske formuleringer, der indeholder lave koncentrationer af peroxid, til behandling eller forebyggelse af vaginale infektioner
AR017925A1 (es) Una formulacion acuosa para verter, topicamente aceptable, adaptada para su aplicacion externa localizada en un animal, su uso y un metodo para formularla
CO5170438A1 (es) Proceso para la preparacion de un comprimido de betahistina de liberacion controlada por granulacion en estado fundido y comprimido de liberacion controlada de betahistina obtenido mediante dicho proceso
ES2191426T3 (es) Composiciones estables que comprenden levosimendano y acido alginico.